Biophytis surges after mid-stage study results for COVID-19 treatment

Biophytis SA

07/09/2022 12:30

** U.S.-listed shares of Paris-based biotech co Biophytis SA
 BPTS.O  jump 45% to $1.36 premarket; top pct. gainer and among
top three heaviest vols. across U.S. exchanges
    ** Co reports mid-stage trial results of its drug candidate
Sarconeos targeting COVID-19-related respiratory failure
 urn:newsml:reuters.com:*:nEQlCR3Za
    ** Sarconeos was found to reduce the risk and progression of
respiratory failure or early death at 28 days compared to
placebo
    ** Sarconeos "could be used in combination with certain
anti-viral and/or anti-inflammatory drugs" - CEO Stanislas
Veillet
    ** France-listed stock  ALBPS.PA  up 28%
    ** U.S. stock has fallen 82.4% this year

 (Reporting by Ruhi Soni and Leroy Leo in Bengaluru)
 ((Ruhi.Soni@thomsonreuters.com
Twitter: https://twitter.com/ruhithere))